Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2019 08:05 ET | Source: Equillium

Equillium to Present New Data and Insights on the CD6-ALCAM Pathway in Lupus Nephritis at ACR 2019

LA JOLLA, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
October 01, 2019 16:05 ET | Source: Equillium

Equillium Announces Initiation of the EQUALISE Phase 1b Clinical Trial of Itolizumab for Patients with Lupus Nephritis and Provides Business Update

Company secures up to $20 million debt facility with Silicon Valley Bank and Oxford Finance LLC Company receives exclusive rights to negotiate licensing rights to develop and commercialize itolizumab...
September 17, 2019 16:07 ET | Source: Equillium

Equillium to Host Business Update Call on October 1, 2019

LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat...
August 27, 2019 16:07 ET | Source: Equillium

Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference

LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
August 12, 2019 16:07 ET | Source: Equillium

Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights

Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...
July 10, 2019 08:07 ET | Source: Equillium

Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma

LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
May 23, 2019 16:07 ET | Source: Equillium

Equillium to Present at Jefferies 2019 Healthcare Conference

LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
May 13, 2019 16:07 ET | Source: Equillium

Equillium Reports First Quarter 2019 Financial Results and Recent Highlights

EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of-concept trials of itolizumab (EQ001) in uncontrolled...
May 06, 2019 08:30 ET | Source: Equillium

Equillium Expands Scientific and Clinical Advisory Team

LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
April 16, 2019 16:07 ET | Source: Equillium

Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day

LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce...